Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

1501. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics

Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1997 DARE.

1502. Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis: the EATHIS Eco Research GrouEuropean Acute Transfusion Hepatitis Interferon Study

Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis: the EATHIS Eco Research GrouEuropean Acute Transfusion Hepatitis Interferon Study Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis: the EATHIS Eco Research GrouEuropean Acute Transfusion Hepatitis Interferon Study Cost-effectiveness of screening blood donors for hepatitis C and non-A, non-B, non-C hepatitis: the EATHIS Eco Research GrouEuropean Acute (...) Transfusion Hepatitis Interferon Study Colin C, Vergnon P, Jullien A M, Excoffier S, Matillon Y, Trepo C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A two-test approach (alanine aminotransferase assay (ALT) and tests for antibodies

1997 NHS Economic Evaluation Database.

1503. Cost effectiveness of hepatitis A virus immunisation in Spain

Cost effectiveness of hepatitis A virus immunisation in Spain Cost effectiveness of hepatitis A virus immunisation in Spain Cost effectiveness of hepatitis A virus immunisation in Spain Arnal J M, Frisas O, Garuz R, Antronanzas F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability (...) of the study and the conclusions drawn. Health technology Hepatitis A Virus (HAV) immunisation. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Children aged 15 months, adolescents aged 13-14 years (either at high risk or not), young adults (around 20 years of age) and adults at high risk of acquiring the disease. The high risk group was defined as those travelling to endemic areas for periods longer than 6 months (either continuously

1997 NHS Economic Evaluation Database.

1504. Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs

Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs Fabrizi F, Lunghi G, Raffaele L, Guarnori I, Bacchini G, Corti M, Pagano A, Erba G, Locatelli F Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Control of hepatitis C virus (HCV) by using third generation screening assays (ELISA and immunoblot) among chronic haemodialysis (HD) patients. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study

1997 NHS Economic Evaluation Database.

1505. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation

Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost (...) -effectiveness evaluation Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Re-vaccination of chronic dialysis patients, who had not responded to a reinforced protocol of hepatitis B

1997 NHS Economic Evaluation Database.

1506. Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections

Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human immunodeficiency virus type 1 infections Value and cost-effectiveness of screening blood donors for antibody to hepatitis B core antigen as a way of detecting window-phase human (...) immunodeficiency virus type 1 infections Busch M P, Dodd R Y, Lackritz E M, Aubuchon J P, Birkmeyer J D, Petersen L R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Screening blood donors for antibody to hepatitis B core antigen (anti-HBc

1997 NHS Economic Evaluation Database.

1507. Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation

Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation Burbach G J, Bienzle U, Neuhaus R, Hopf U, Metzger W G, Pratschke J, Neuhaus P Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Applying long-term fortnightly intramuscular anti-HBs immunoprophylaxis (1000 IU of anti HBS, Hepatitis-B-Immunoglobulin, Behring) to prevent reinfection with HBV (hepatitis B virus) after

1997 NHS Economic Evaluation Database.

1508. Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases

Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases Economic implications of hepatic arterial infusion chemotherapy in treatment of nonresectable colorectal liver metastases Durand-Zaleski I, Roche B, Buyse M, Carlson R, O'Connell M J, Rougier P, Chang A E, Sondak V K, Kemeny M M, Allen-Mersh T G, Fagniez (...) P L, Le Bourgeois J P, Piedbois P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using hepatic arterial infusion (HAI)of 5-fluoro-2'-deoxyuridine versus supportive care or intravenous chemotherapy in the treatment

1997 NHS Economic Evaluation Database.

1509. Percutaneous ethanol injection therapy as a treatment for hepatic cancer

Percutaneous ethanol injection therapy as a treatment for hepatic cancer Percutaneous ethanol injection therapy as a treatment for hepatic cancer Percutaneous ethanol injection therapy as a treatment for hepatic cancer Corabian P Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Corabian P. Percutaneous ethanol injection therapy (...) as a treatment for hepatic cancer. Alberta Heritage Foundation for Medical Research (AHFMR) 1997: 17 Authors' objectives Hepatocellular carcinoma (HCC) is increasingly detected following widespread sonographic screening of high risk patients, especially those with liver cirrhosis and chronic viral hepatitis. Although it occurs less frequently in Northern and Western Europe and in North America than in other parts of the world, in the last 15 years the incidence of HCC has been increasing steadily

1997 Health Technology Assessment (HTA) Database.

1510. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. (Abstract)

Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Fulminant hepatic necrosis ("halothane hepatitis") is an unusual and often fatal complication of halothane anaesthesia. It is mediated by immune sensitisation in susceptible individuals to trifluoroacetylated liver protein neoantigens, formed by oxidative halothane metabolism. The seminal event in halothane hepatitis is hepatic metabolism, yet the enzyme responsible (...) oxidative halothane metabolism. Inhibition of P450 2E1 by a single preoperative oral disulfiram dose greatly diminished production of the halothane metabolite responsible for the neoantigen formation that initiates halothane hepatitis. Single-dose disulfiram may provide effective prophylaxis against halothane hepatitis.

1996 Lancet Controlled trial quality: uncertain

1511. Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination

Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination Hepatitis A infection in aircrews: risk of infection and cost-benefit analysis of hepatitis A vaccination Gutersohn T, Steffen R, Van Damme P, Holdener F, Beutels P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Hepatitis A Vaccination Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Swissair aircrews. Setting European based carrier with flights to international destinations. Dates to which data relate The data for the effectiveness and resource use analyses

1996 NHS Economic Evaluation Database.

1512. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C

A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1996 NHS Economic Evaluation Database.

1513. Treatment of chronic hepatitis C with alpha-interferon: an analysis of the literature

Treatment of chronic hepatitis C with alpha-interferon: an analysis of the literature Treatment of chronic hepatitis C with alpha-interferon: an analysis of the literature Treatment of chronic hepatitis C with alpha-interferon: an analysis of the literature Niederau C, Heintges T, Haussinger D Authors' objectives To evaluate whether the type, dose, and duration of interferon treatment affect its short- and long-term responses, and to analyse whether the presence of liver cirrhosis predicts (...) response rates. Searching MEDLINE was searched from 1986 to 1993; no search terms are given. Additional material was located by searching articles and abstracts published in the journals of the American and European Associations for the Study of Liver Diseases, and the proceedings of recent international meetings referring to research in viral hepatitis. Study selection Study designs of evaluations included in the review Randomised controlled trials, except those with a crossover design, were included

1996 DARE.

1514. The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis

The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis The efficacy of interferon alfa in chronic hepatitis B: a review and meta-analysis Malaguarnera M, Restuccia S, Receputo G, Giugno I, Pistone G, Trovato B A Authors' objectives To assess the effectiveness of interferon (IFN)-alpha in patients with chronic hepatitis B. Searching MEDLINE was searched (search dates are unclear (...) ). The abstracts from congresses on gastroenterology and liver disease were also examined. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) with a post-treatment follow-up of at least 12 months planned and providing adequate outcome data. Trials in which patients were coinfected with hepatitis delta virus were excluded, as were trials in which IFN-alpha was used in combination with antiviral agents. Specific interventions included in the review Various

1996 DARE.

1515. A meta-analysis of interferon-alpha treatment of hepatitis D virus infection

A meta-analysis of interferon-alpha treatment of hepatitis D virus infection A meta-analysis of interferon-alpha treatment of hepatitis D virus infection A meta-analysis of interferon-alpha treatment of hepatitis D virus infection Malaguarnera M, Restuccia S, Pistone G, Ruello P, Giugno I, Trovato B A Authors' objectives To evaluate the efficacy of interferon-alpha (IFN-alpha) in the treatment of chronic hepatitis D virus (HDV) infection. Searching MEDLINE was searched from 1987 to 1994 (...) the limited effectiveness of treatment and the need for further trials are probably warranted. Bibliographic details Malaguarnera M, Restuccia S, Pistone G, Ruello P, Giugno I, Trovato B A. A meta-analysis of interferon-alpha treatment of hepatitis D virus infection. Pharmacotherapy 1996; 16(4): 609-614 PubMedID Other publications of related interest Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc

1996 DARE.

1516. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis

Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis Torre D, Tambini R Authors' objectives To provide a systematic overview of recombinant interferon (IFN)-treatment of children with chronic hepatitis B and to estimate the average efficacy of IFN-treatment. Searching MEDLINE and Index Medicus were searched from (...) January 1986 to November 1995. International congress abstracts, documentation from pharmaceutical firms and references of selected papers were also examined. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Recombinant IFN-2a and recombinant IFN-2b. Participants included in the review Children with chronic hepatitis B, aged from 1.5 to 17 years, were included. Outcomes assessed

1996 DARE.

1517. Interferon as treatment for acute hepatitis C: a meta-analysis

Interferon as treatment for acute hepatitis C: a meta-analysis Interferon as treatment for acute hepatitis C: a meta-analysis Interferon as treatment for acute hepatitis C: a meta-analysis Camma C, Almasio P, Craxi A Authors' objectives To evaluate the efficacy of short-term (3 months), low-dose (3 million units, 3 times a week) interferon (IFN) as treatment for acute hepatitis C. Searching MEDLINE was searched from January 1990 to December 1994 for English language publications, using (...) the following keywords: 'clinical trials', 'interferons', 'acute hepatitis C', 'acute hepatitis non-A' and 'acute hepatitis non-B'. Reference lists of all the available review articles and trials were also examined, and some authors were contacted. Study selection Study designs of evaluations included in the review Randomised and non-randomised controlled studies. Inclusion criteria were: 1. diagnosis of acute non-A, non-B hepatitis or type C hepatitis, either post-transfusion or sporadic; 2. a no-treatment

1996 DARE.

1518. Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy

Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy Overview of randomized clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy Fabbri A, Magrini N, Bianchi G, Zoli M, Marchesini G Authors' objectives To examine the effectiveness of oral branched-chain amino acid (BCAA (...) ) supplements in the prevention and treatment of chronic hepatic encephalopathy (HE). Searching MEDLINE was searched from January 1976 to December 1992; the search strategy is given. Additional literature was obtained by manually searching references lists from other reviews and articles, and by contacting investigators in this field. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) of treatment with oral BCAA were included. The control treatments

1996 DARE.

1519. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1996 DARE.

1520. Recombinant hepatitis B vaccine use in chronic hemodialysis patients

Recombinant hepatitis B vaccine use in chronic hemodialysis patients Recombinant hepatitis B vaccine use in chronic hemodialysis patients Recombinant hepatitis B vaccine use in chronic hemodialysis patients Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L, Crepaldi M, Erba G, Locatelli F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Recombinant Hepatitis B Vaccine for chronic hemodialysis patients. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Chronic hemodialysis patients. Setting Hospital. The economic study was carried out in Lecco, Italy. Dates to which data relate The dates associated with the effectiveness and resource use data

1996 NHS Economic Evaluation Database.